RT Book, Section
A1 McQuaid, Kenneth R.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184170657
T1 Inflammatory Bowel Disease
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184170657
RD 2024/04/19
AB KEY  CLINICAL  UPDATES  IN  INFLAMMATORY  BOWEL  DISEASEFor  patients  who  require  more  than  one  course  of  corticosteroid  therapy  every  1–2  years  for  symptomatic  relapse,  treatment  should  be  ‘stepped  up’  to  include  a  thiopurine  (azathioprine  or  mercaptopurine)  or  a  biologic  agent.A  2020  American  Gastroenterological  Association  guideline  recommends  either  infliximab  or  vedolizumab  as  first-line  therapies  for  moderate  to  severe  colitis  based  on  their  efficacy  and  safety  profiles.These  two  agents  had  the  highest  rankings  of  all  biologic  agents  for  induction  of  clinical  remission  in  a  2020  network  meta-analysis.Although  infliximab  may  be  the  more  effective  agent  (especially  for  severe  disease),  vedolizumab  may  be  the  preferred  first-line  therapy  in  patients  who  are  elderly  or  have  increased  medical  comorbidities  due  to  its  significantly  lower  incidence  of  infectious  complications.